Literature DB >> 9440894

[Stent implantation and balloon dilatation in the treatment of stenosis and obstruction of the lacrimal apparatus].

K Wilhelm1, J Textor, U Hofer, T Böker, H Strunk, H Schild.   

Abstract

PURPOSE: To evaluate treatment of epiphora caused by obstructions of the nasolacrimal duct system with balloon dilatation and stent implantation.
MATERIAL AND METHODS: 28 dacryocystoplasties were performed in 20 patients with complete (n = 7) or incomplete (n = 13) obstruction of the nasolacrimal duct system.
RESULTS: Dacryocystoplasty was technically successful performed in 26 cases (93%). Recanalisation was not achieved in two patients with complete obstructions. 17 patients showed complete or partial resolution of epiphora during follow-up of up to two years (clinical success 85%). Complete reobstruction occurred only in one patient 9 months after balloon dilatation and recanalisation was not possible.
CONCLUSION: With a technical success rate of 93% and a clinical success rate of 85% dacryocystoplasty is a non-operative alternative for treatment of epiphora caused by obstructions of the nasolacrimal duct system.

Entities:  

Mesh:

Year:  1997        PMID: 9440894     DOI: 10.1055/s-2007-1015568

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  3 in total

1.  [Balloon dilatation of the canaliculus communis for chronic epiphora].

Authors:  U Lachmund; D Ammann; A Forrer; C Petralli; L Remonda; T Roeren; F Vonmoos; K Wilhelm
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

2.  [Importance of imaging diagnostics and interventional therapy for diseases of the lacrimal drainage canals].

Authors:  A Bink; M Lüchtenberg; J Berkefeld
Journal:  Radiologe       Date:  2008-12       Impact factor: 0.635

3.  [Dacryocystorhinostomy as part of the interdisciplinary treatment of lacrimal duct].

Authors:  S Herberhold; R Lindner; K Wilhelm; M Kühnemund; A Schröck; M Jakob; M Förl; E Domeier; T J Mäueler; M S Bedar; S Keiner; A Weißbach
Journal:  HNO       Date:  2013-10       Impact factor: 1.284

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.